Literature DB >> 20167041

High inflammatory activity related to the number of metabolic syndrome components.

Bahadir Kirilmaz1, Fatih Asgun, Emin Alioglu, Ertugrul Ercan, Istemihan Tengiz, Ugur Turk, Serkan Saygi, Filiz Ozerkan.   

Abstract

It has been known that each component of the metabolic syndrome (MS) has an atherogenic potential and increases the risk of cardiovascular events. Therefore, patients who have MS are candidates for the development of atherosclerosis and accompanying complications. In this study, the authors assessed the levels of acute phase reactants as an indicator of inflammation in patients with MS. Twenty-five patients with recently diagnosed MS and not treated before who had at least 3 of 5 diagnostic criteria of MS listed in the Third Report of the Adult Treatment Panel National Cholesterol Education Program (NCEP-ATP III) guidelines were included in the study. Twenty healthy patients constituted the control group. Inflammatory parameters were compared between the groups. There was no significant difference between the MS and control group with regard to age and sex. White blood cell count (/mm(3)), high-sensitivity C-reactive protein (hs-CRP), uric acid, interleukin (IL) 6, and fibrinogen levels were found to be significantly higher in the MS group. Number of MS components was strongly correlated with serum levels of hs-CRP (r=0.688, P=.0001), IL-6 (r=0.546, P=.0001), fibrinogen (r=0.551, P=.0001), uric acid (r=0.517, P=.0001), and leucocyte count (/mm(3)) (r=0.456, P=.002). Inflammation plays an important role in atherosclerotic complications, which is activated in MS. Increased number of MS components are strongly associated with elevated inflammatory and metabolic markers. Measurement of serum inflammatory parameters in patients with MS may be beneficial in detection and management of cardiovascular events and in the assessment of efficacy of treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167041      PMCID: PMC8673215          DOI: 10.1111/j.1751-7176.2009.00229.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  43 in total

1.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

2.  The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men.

Authors:  A Tchernof; B Lamarche; D Prud'Homme; A Nadeau; S Moorjani; F Labrie; P J Lupien; J P Després
Journal:  Diabetes Care       Date:  1996-06       Impact factor: 19.112

3.  Insulin resistance early in adulthood in subjects born with intrauterine growth retardation.

Authors:  D Jaquet; A Gaboriau; P Czernichow; C Levy-Marchal
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

4.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

Authors:  R B Devereux; D R Alonso; E M Lutas; G J Gottlieb; E Campo; I Sachs; N Reichek
Journal:  Am J Cardiol       Date:  1986-02-15       Impact factor: 2.778

Review 5.  Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker.

Authors:  I Jialal; S Devaraj
Journal:  Am J Clin Pathol       Date:  2001-12       Impact factor: 2.493

6.  Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects.

Authors:  L Groop; C Forsblom; M Lehtovirta; T Tuomi; S Karanko; M Nissén; B O Ehrnström; B Forsén; B Isomaa; B Snickars; M R Taskinen
Journal:  Diabetes       Date:  1996-11       Impact factor: 9.461

7.  Association of echocardiographic left ventricular mass with body size, blood pressure and physical activity (the Framingham Study).

Authors:  D D Savage; D Levy; A L Dannenberg; R J Garrison; W P Castelli
Journal:  Am J Cardiol       Date:  1990-02-01       Impact factor: 2.778

8.  Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease.

Authors:  J R Petrie; S Ueda; D J Webb; H L Elliott; J M Connell
Journal:  Circulation       Date:  1996-04-01       Impact factor: 29.690

Review 9.  Insulin resistance and chronic cardiovascular inflammatory syndrome.

Authors:  José Manuel Fernández-Real; Wifredo Ricart
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

10.  Linkage of chromosomal markers on 4q with a putative gene determining maximal insulin action in Pima Indians.

Authors:  M Prochazka; S Lillioja; J F Tait; W C Knowler; D M Mott; M Spraul; P H Bennett; C Bogardus
Journal:  Diabetes       Date:  1993-04       Impact factor: 9.461

View more
  15 in total

Review 1.  Mineralocorticoid receptor antagonists and the metabolic syndrome.

Authors:  Amir Tirosh; Rajesh Garg; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

2.  Association between high-sensitivity C-reactive protein and hyperuricemia.

Authors:  Tuo Yang; Xiang Ding; Yi-Lun Wang; Chao Zeng; Jie Wei; Hui Li; Yi-Lin Xiong; Shu-Guang Gao; Yu-Sheng Li; Guang-Hua Lei
Journal:  Rheumatol Int       Date:  2016-02-10       Impact factor: 2.631

3.  Metabolic syndrome and neurotrophins: effects of metformin and non-steroidal antiinflammatory drug treatment.

Authors:  Mariyana G Hristova
Journal:  Eurasian J Med       Date:  2011-12

4.  The associations of serum uric acid level and hyperuricemia with knee osteoarthritis.

Authors:  Xiang Ding; Chao Zeng; Jie Wei; Hui Li; Tuo Yang; Yi Zhang; Yi-Lin Xiong; Shu-Guang Gao; Yu-Sheng Li; Guang-Hua Lei
Journal:  Rheumatol Int       Date:  2016-01-07       Impact factor: 2.631

Review 5.  Why Does Hyperuricemia Not Necessarily Induce Gout?

Authors:  Wei-Zheng Zhang
Journal:  Biomolecules       Date:  2021-02-14

6.  Acute phase reactant dynamics and incidence of microvascular dysfunctions in type 2 diabetes mellitus.

Authors:  Majid Khazaei
Journal:  J Res Med Sci       Date:  2011-12       Impact factor: 1.852

7.  Detection of homocysteine and C-reactive protein in the saliva of healthy adults: comparison with blood levels.

Authors:  Michael C Dillon; Daniel C Opris; Rafal Kopanczyk; Jackie Lickliter; Hayley N Cornwell; Edward G Bridges; Andrea M Nazar; Kristie Grove Bridges
Journal:  Biomark Insights       Date:  2010-07-20

8.  Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients.

Authors:  Beth L Abramson; Pascale Benlian; Mary E Hanson; Jianxin Lin; Arvind Shah; Andrew M Tershakovec
Journal:  Lipids Health Dis       Date:  2011-08-22       Impact factor: 3.876

9.  Interleukin-18 can predict pre-clinical atherosclerosis and poor glycemic control in type 2 diabetes mellitus.

Authors:  Zhian M Ibrahim Dezayee
Journal:  Int J Appl Basic Med Res       Date:  2011-07

Review 10.  Review of hyperuricemia as new marker for metabolic syndrome.

Authors:  Laura Billiet; Sarah Doaty; James D Katz; Manuel T Velasquez
Journal:  ISRN Rheumatol       Date:  2014-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.